Market Cap (In USD)
10.74 Million
Revenue (In USD)
5.09 Million
Net Income (In USD)
-5.8 Million
Avg. Volume
17.00
- Currency
- USD
- Country
- Healthcare
- Open
- -
- Prev. Close
- -
- Day Range
- -
- Year Range
- 0.02-0.06
- PE
- -
- EPS
- -
- Beta Value
- 1.155
- ISIN
- AU000000ACR3
- CUSIP
- -
- CIK
- -
- Shares
- -
- Earnings Annoncement
- -
Company Profile
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Michael John Kotsanis B.Sc., BSc, GradDipBus, MBus
- Employee Count
- -
- Website
- https://www.acrux.com.au
- Ipo Date
- 2010-06-08
- Details
- Acrux Limited, together with its subsidiaries, develops and commercializes generic and topical pharmaceuticals in Australia, Europe, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of adult males who have low or no testosterone. It also provides estradiol sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause. The company was incorporated in 1998 and is based in West Melbourne, Australia.
More Stocks
-
KLD
-
CFG
-
0202
-
2347
-
183190Asia Cement Co.,Ltd.
183190
-
TZPC
-
MAM
-
US44891N2080IAC InterActive Corp.
US44891N2080